Last reviewed · How we verify

Institut Bergonié — Portfolio Competitive Intelligence Brief

Institut Bergonié pipeline: 1 marketed, 0 filed, 2 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
target treatment target treatment marketed CDK4/6 inhibitor CDK4/6 Oncology
At the discretion of the investigator At the discretion of the investigator phase 3
Ifosfamide or dacarbazine Ifosfamide or dacarbazine phase 3 Alkylating agent DNA (non-specific alkylation) Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Jiangsu Simcere Pharmaceutical Co., Ltd. · 2 shared drug classes
  2. Asahi Kasei Pharma Corporation · 1 shared drug class
  3. BeBetter Med Inc · 1 shared drug class
  4. Astellas Pharma China, Inc. · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Baxter · 1 shared drug class
  7. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  8. Alberta Health services · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Institut Bergonié:

Cite this brief

Drug Landscape (2026). Institut Bergonié — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/institut-bergoni. Accessed 2026-05-14.

Related